FFM
CTMX icon

Fairmount Funds Management’s CytomX Therapeutics CTMX Stock Holding History

Fairmount Funds Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,896,582
Closed -$8.85M – 18
2025
Q2 		$8.85M Buy
+3,896,582
New +$6.28M 1.15% 17

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Fairmount Funds Management's CTMX Position: Q3 2025 in Review

Fairmount Funds Management sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 3,896,582 shares — an estimated $8.85M sold.

Fairmount Funds Management first reported a position in CTMX in Q2 2025 and held it in 1 quarter. The position peaked at $8.85M in Q2 2025. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

  • Fairmount Funds Management reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fairmount Funds Management sold 3,896,582 CytomX Therapeutics shares in Q3 2025, an estimated $8.85M.
  • Fairmount Funds Management first reported a position in CytomX Therapeutics in Q2 2025 and held it in 1 quarter.
  • Fairmount Funds Management's CytomX Therapeutics position peaked at $8.85M in Q2 2025.
  • 103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Fairmount Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.